We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Cumberland Pharmaceuticals (CPIX - Free Report) closed at $5.95 in the latest trading session, marking a -0.32% move from the prior day. This change lagged the S&P 500's daily loss of 0.04%. At the same time, the Dow lost 0.51%, and the tech-heavy Nasdaq gained 0.21%.
Coming into today, shares of the pharmaceutical company had gained 1.52% in the past month. In that same time, the Medical sector lost 5.37%, while the S&P 500 gained 4.65%.
Investors will be hoping for strength from CPIX as it approaches its next earnings release. On that day, CPIX is projected to report earnings of -$0.11 per share, which would represent a year-over-year decline of 22.22%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.70 million, up 24.56% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.24 per share and revenue of $50.11 million, which would represent changes of -700% and +22.99%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CPIX. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CPIX is currently a Zacks Rank #1 (Strong Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 50, which puts it in the top 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CPIX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
Cumberland Pharmaceuticals (CPIX - Free Report) closed at $5.95 in the latest trading session, marking a -0.32% move from the prior day. This change lagged the S&P 500's daily loss of 0.04%. At the same time, the Dow lost 0.51%, and the tech-heavy Nasdaq gained 0.21%.
Coming into today, shares of the pharmaceutical company had gained 1.52% in the past month. In that same time, the Medical sector lost 5.37%, while the S&P 500 gained 4.65%.
Investors will be hoping for strength from CPIX as it approaches its next earnings release. On that day, CPIX is projected to report earnings of -$0.11 per share, which would represent a year-over-year decline of 22.22%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.70 million, up 24.56% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.24 per share and revenue of $50.11 million, which would represent changes of -700% and +22.99%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CPIX. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CPIX is currently a Zacks Rank #1 (Strong Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 50, which puts it in the top 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CPIX in the coming trading sessions, be sure to utilize Zacks.com.